When used as monotherapy, patients with RAS pathway co-mutations and/or high mutational burden (>6 mutations) were less likely to respond173,174, suggesting the importance of combination therapy (under evaluation in both newly diagnosed and relapsed IDH2-mutated AML). Here, IDH2 is linked to acute myeloid leukemia.